Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: The effect of statins and fibrates on the risk of chronic obstructive pulmonary disease (COPD) remains unclear. The aim of this study was to investigate the effects of statins and fibrates on the risk of COPD in patients with hyperlipidemia.
Patients And Methods: This study involved a retrospective cohort with a follow-up period of 6 years. We identified patients who were diagnosed as having hyperlipidemia between 2000 and 2016 from Taiwan's National Health Insurance Research Database. A Cox proportional hazard model was used to estimate the risk of COPD among different groups. The dose-related effects of statins and fibrates on the risk of COPD were evaluated according to the defined daily dose (DDD).
Results: Patients with hyperlipidemia not using statins and fibrates (group II) had a significantly higher risk of COPD compared with their comparison group, with an adjusted hazard ratio (HR) of 1.091 [95% confidence interval (CI): 1.034-1.152, < 0.01]. Dose-dependent reduction in the risk of COPD was observed in patients with hyperlipidemia using statins or fibrates compared with patients not using them. Moreover, with an increase in cumulative exposure, a reduced risk of COPD was observed in patients using more than 361 DDDs, with an adjusted HR of 0.474 (95% CI: 0.401-0.559, < 0.001). Patients on fibrate monotherapy using more than 541 DDDs were observed to have an adjusted HR of 0.454 (95% CI: 0.226-0.910, < 0.05) and those on statin monotherapy with over 361 DDDs were noted to have an adjusted HR of 0.583 (95% CI: 0.459-0.740, < 0.001).
Conclusion: This study demonstrated that an increase in the cumulative exposure of statins and fibrates significantly reduced the risk of COPD in patients with hyperlipidemia, and the risk reduction appeared to be significantly dose dependent.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585814 | PMC |
| http://dx.doi.org/10.2147/COPD.S267017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction Chronic Obstructive Pulmonary Disease (COPD) is increasingly recognized not only as a pulmonary condition but as a systemic disorder with significant cardiovascular implications. Acute exacerbations of COPD (AECOPD) further elevate this risk, potentially through a heightened prothrombotic state. This study aimed to evaluate and compare the levels of select prothrombotic biomarkers - fibrinogen, C-reactive protein (CRP), D-dimer, von Willebrand Factor (vWF), homocysteine, lactate dehydrogenase (LDH), and platelet-to-lymphocyte ratio (PLR) - in patients with stable COPD and AECOPD, and to assess their diagnostic and prognostic significance.
View Article and Find Full Text PDFDLCO in HIV Patients and Their Association with CD4 and VL.
HIV AIDS (Auckl)
September 2025
Department of Respiratory Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.
Introduction: The advent of highly active antiretroviral therapy (HAART) has changed infection by human immunodeficiency virus (HIV) from an acute disease to a manageable chronic condition; however, pulmonary complications continue to affect patient quality of life. The goal of this research was to examine the link between CD4+ levels, viral load, and respiratory function in patients infected with HIV.
Methods: Patients were grouped as HIV-infected and non-infected (1:2 ratio).
Dipeptidyl peptidase 1 inhibitors for inflammatory respiratory diseases: mechanisms, clinical trials, and therapeutic prospects.
Front Pharmacol
August 2025
Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Dipeptidyl peptidase 1 (DPP1) inhibitors constitute a major advance in respiratory disease therapeutics. Through selective blockade of neutrophil serine protease (NSP) activation, these agents establish novel treatment paradigms for inflammatory respiratory conditions characterized by neutrophil-driven pathology. This comprehensive review examines the development status, clinical efficacy, and safety profile of DPP1 inhibitors in neutrophil-driven diseases, particularly non-cystic fibrosis bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD).
View Article and Find Full Text PDFAssociation Between Urban Green Space and Acute Exacerbations of COPD in Korea: A Nationwide Study Using the NHIS-NSC Cohort.
Int J Chron Obstruct Pulmon Dis
September 2025
Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea.
Background: Chronic obstructive pulmonary disease (COPD) is a major health concern in Korea, with a higher burden of acute exacerbations (AE-COPD) compared to Western populations. Environmental exposures such as smoking and air pollution are known contributors, but the impact of urban green space remains underexplored.
Methods: We conducted a cohort study using the Korean National Health Insurance Service-National Sample Cohort (2006-2019), including 5,171 patients aged ≥40 years with at least two COPD-related prescriptions within one year.
Cross-Trait Genome-Wide Association Study Identifies Shared Genetic Risk Loci Between COPD and Five Autoimmune Diseases.
Int J Chron Obstruct Pulmon Dis
September 2025
Department of Respiratory Medicine, First Affiliated Hospital of Gannan Medical University, Ganzhou City, Jiangxi Province, People's Republic of China.
Background: Chronic obstructive pulmonary disease (COPD) frequently co-occurs with autoimmune diseases (ADs), yet their shared genetic basis remains incompletely understood. This study aimed to evaluate genetic correlations between COPD and seven ADs and identify shared genetic risk loci underlying this comorbidity.
Methods: We integrated summary statistics from large-scale genome-wide association studies (GWAS) of COPD and seven ADs in European populations.